CDPF1

Summary

CDPF1 (cysteine rich DPF motif domain containing 1, HGNC:33710) is a protein-coding gene on chromosome 22q13.31, encoding Cysteine-rich DPF motif domain-containing protein 1 (Q6NVV7).

At a glance

• GWAS associations: 63
• Clinical variants (ClinVar): 76 total — 1 pathogenic
• MANE Select transcript: NM_207327

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33710
Approved symbol	CDPF1
Name	cysteine rich DPF motif domain containing 1
Location	22q13.31
Locus type	gene with protein product
Status	Approved
Aliases	CDKN1A
Ensembl gene	ENSG00000205643
Ensembl biotype	protein_coding
Entrez	150383

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 19 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000314567, ENST00000381037, ENST00000404583, ENST00000404744, ENST00000474256, ENST00000475605, ENST00000904358, ENST00000904359, ENST00000904360, ENST00000904361, ENST00000904362, ENST00000904363, ENST00000904364, ENST00000904365, ENST00000904366, ENST00000904367, ENST00000931570, ENST00000931571, ENST00000931572, ENST00000931573, ENST00000962067, ENST00000962068

RefSeq mRNA: 1 — MANE Select: NM_207327 NM_207327

CCDS: CCDS33670

Canonical transcript exons

ENST00000314567 — 4 exons

Exon	Start	End
ENSE00001487305	46244013	46245238
ENSE00001916377	46250256	46250293
ENSE00002287394	46248172	46248284
ENSE00003511837	46247110	46247221

Expression profiles

Bgee: expression breadth ubiquitous, 174 present calls, max score 86.75.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.5664 / max 27.0833, expressed in 1664 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
194601	4.5664	1664

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	86.75	silver quality
tibialis anterior	UBERON:0001385	85.72	gold quality
apex of heart	UBERON:0002098	84.37	gold quality
muscle layer of sigmoid colon	UBERON:0035805	82.72	gold quality
right adrenal gland	UBERON:0001233	82.55	gold quality
lower esophagus	UBERON:0013473	82.47	gold quality
lower esophagus muscularis layer	UBERON:0035833	82.47	gold quality
right adrenal gland cortex	UBERON:0035827	82.11	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	82.01	gold quality
left adrenal gland	UBERON:0001234	81.86	gold quality
left adrenal gland cortex	UBERON:0035825	81.79	gold quality
granulocyte	CL:0000094	81.77	gold quality
gastrocnemius	UBERON:0001388	81.37	gold quality
body of uterus	UBERON:0009853	81.22	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.14	gold quality
adrenal cortex	UBERON:0001235	81.14	gold quality
muscle of leg	UBERON:0001383	81.07	gold quality
right lobe of thyroid gland	UBERON:0001119	81.03	gold quality
mucosa of stomach	UBERON:0001199	80.59	gold quality
right ovary	UBERON:0002118	80.56	gold quality
right coronary artery	UBERON:0001625	80.52	gold quality
deltoid	UBERON:0001476	80.51	silver quality
endocervix	UBERON:0000458	80.49	gold quality
heart left ventricle	UBERON:0002084	80.38	gold quality
popliteal artery	UBERON:0002250	80.38	gold quality
tibial artery	UBERON:0007610	80.37	gold quality
left ovary	UBERON:0002119	80.35	gold quality
left ventricle myocardium	UBERON:0006566	80.14	gold quality
cardiac muscle of right atrium	UBERON:0003379	80.10	gold quality
cardiac ventricle	UBERON:0002082	80.06	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting CDPF1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-4292	99.16	65.57	1767
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-4704-3P	98.28	69.33	1300

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdpf1	ENSDARG00000095705
mus_musculus	Cdpf1	ENSMUSG00000064284
rattus_norvegicus	Cdpf1	ENSRNOG00000032846
drosophila_melanogaster	CG11755	FBGN0037611
caenorhabditis_elegans		WBGENE00008434
caenorhabditis_elegans		WBGENE00271706

Protein

Protein identifiers

Cysteine-rich DPF motif domain-containing protein 1 — Q6NVV7 (reviewed: Q6NVV7)

All UniProt accessions (4): Q6NVV7, F6RAJ7, F6UL18, H9KV78

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the CDPF1 family.

RefSeq proteins (1): NP_997210* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR018785	CDPF1_dom	Domain
IPR042426	CDPF1	Family

Pfam: PF10170

UniProt features (6 total): sequence variant 2, chain 1, region of interest 1, compositionally biased region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6NVV7-F1	87.30	0.67

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 1052 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, SA_G2_AND_M_PHASES, WU_APOPTOSIS_BY_CDKN1A_VIA_TP53, MODULE_52, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, AP1_01, GOBP_POSITIVE_REGULATION_OF_DNA_REPLICATION, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_RESPONSE_TO_IONIZING_RADIATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_DNA_DAMAGE_BY_P53_CLASS_MEDIATOR, FREAC2_01, HNF3ALPHA_Q6, GOBP_NEGATIVE_REGULATION_OF_SMOOTH_MUSCLE_CELL_PROLIFERATION, HARRIS_HYPOXIA

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

226 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDPF1	PKDREJ	Q9NTG1	575
CDPF1	ATXN10	Q9UBB4	533
CDPF1	WNT7B	P56706	457
CDPF1	DNLZ	Q5SXM8	350
CDPF1	PRORP	O15091	347
CDPF1	WDR89	Q96FK6	347
CDPF1	MYH8	P13535	317
CDPF1	TMEM203	Q969S6	312
CDPF1	IQUB	Q8NA54	310
CDPF1	PSMD9	O00233	303
CDPF1	TMC6	Q7Z403	234
CDPF1	PAX7	P23759	230
CDPF1	SLC47A1	Q96FL8	213
CDPF1	ARHGAP42	A6NI28	213
CDPF1	SLC47A2	Q86VL8	213

IntAct

56 interactions, top by confidence:

A	B	Type	Score
BHLHE40	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
CREB5	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
CDPF1	DDIT4L	psi-mi:“MI:0915”(physical association)	0.560
CDPF1	TFAP2D	psi-mi:“MI:0915”(physical association)	0.560
CDPF1	CATSPER1	psi-mi:“MI:0915”(physical association)	0.560
FRS3	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
PHLDA1	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
EFEMP2	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
CDPF1	KCTD9	psi-mi:“MI:0915”(physical association)	0.560
VGLL3	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
ZIC1	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
HDAC4	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
CDPF1	ENKD1	psi-mi:“MI:0915”(physical association)	0.560
CDPF1	MISP	psi-mi:“MI:0915”(physical association)	0.560
FAM221A	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
HOXA1	CDPF1	psi-mi:“MI:0915”(physical association)	0.560
CDPF1	DHX34	psi-mi:“MI:0915”(physical association)	0.500
CDPF1	PTGER4	psi-mi:“MI:0915”(physical association)	0.370
CDPF1	USP4	psi-mi:“MI:0914”(association)	0.350
INSR	ATOX1	psi-mi:“MI:0914”(association)	0.350
INSR	RIMOC1	psi-mi:“MI:0914”(association)	0.350
CREB5	CDPF1	psi-mi:“MI:0915”(physical association)	0.000
CDPF1	DDIT4L	psi-mi:“MI:0915”(physical association)	0.000
TFAP2D	CDPF1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (37): CDPF1 (Two-hybrid), CDPF1 (Affinity Capture-MS), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid), CDPF1 (Two-hybrid)

ESM2 similar proteins: A1L2W7, B4GH42, B5E0H4, P06428, P06463, P09543, P13233, P16330, P19709, P19710, P21735, P22158, P22422, P24836, P25484, P26554, P26555, P27229, P28831, P28832, P30734, P36800, P36801, P36803, P36805, P36807, P36809, P36810, P36812, P36815, P50810, P54667, Q02269, Q0VCH3, Q5RFD0, Q5RFL4, Q5XI06, Q5XUN4, Q5ZKB8, Q62240

Diamond homologs: A1L2W7, Q0VCH3, Q5RGZ1, Q5ZKB8, Q6NVV7, Q8R3A2, Q9VHN3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	42
Likely benign	13
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2582285	NM_000389.5(CDKN1A):c.142C>T (p.Arg48Ter)	Pathogenic

SpliceAI

1267 predictions. Top by Δscore:

Variant	Effect	Δscore
22:46247105:CCCA:C	donor_gain	1.0000
22:46247123:ACCAG:A	donor_gain	1.0000
22:46247124:CCAGC:C	donor_gain	1.0000
22:46247127:G:A	donor_gain	1.0000
22:46247140:A:AC	donor_gain	1.0000
22:46247141:C:CC	donor_gain	1.0000
22:46247222:C:CC	acceptor_gain	1.0000
22:46248170:A:AC	donor_gain	1.0000
22:46248171:C:CC	donor_gain	1.0000
22:46248171:CA:C	donor_gain	1.0000
22:46245238:CCT:C	acceptor_gain	0.9900
22:46245240:T:C	acceptor_gain	0.9900
22:46247104:AC:A	donor_gain	0.9900
22:46247105:CC:C	donor_gain	0.9900
22:46247217:GGAGG:G	acceptor_gain	0.9900
22:46247218:GAGG:G	acceptor_gain	0.9900
22:46247219:AGGCT:A	acceptor_loss	0.9900
22:46247220:GG:G	acceptor_gain	0.9900
22:46247223:T:C	acceptor_loss	0.9900
22:46248170:ACAC:A	donor_gain	0.9900
22:46248171:CACC:C	donor_gain	0.9900
22:46245215:C:G	acceptor_gain	0.9800
22:46245239:C:CC	acceptor_gain	0.9800
22:46247104:A:AC	donor_gain	0.9800
22:46247105:C:CC	donor_gain	0.9800
22:46247219:AGG:A	acceptor_gain	0.9800
22:46248171:CACCA:C	donor_gain	0.9800
22:46248282:CATCT:C	acceptor_loss	0.9800
22:46248284:TC:T	acceptor_loss	0.9800
22:46248285:C:CA	acceptor_loss	0.9800

AlphaMissense

800 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:46245224:G:C	F80L	0.991
22:46245224:G:T	F80L	0.991
22:46245226:A:G	F80L	0.991
22:46245230:A:C	S78R	0.984
22:46245230:A:T	S78R	0.984
22:46245232:T:G	S78R	0.984
22:46248246:A:C	F13L	0.980
22:46248246:A:T	F13L	0.980
22:46248248:A:G	F13L	0.980
22:46245209:G:C	F85L	0.979
22:46245209:G:T	F85L	0.979
22:46245211:A:G	F85L	0.979
22:46245173:A:C	F97L	0.974
22:46245173:A:T	F97L	0.974
22:46245175:A:G	F97L	0.974
22:46247206:G:C	S43R	0.974
22:46247206:G:T	S43R	0.974
22:46247208:T:G	S43R	0.974
22:46247185:G:C	F50L	0.973
22:46247185:G:T	F50L	0.973
22:46247187:A:G	F50L	0.973
22:46247121:A:G	C72R	0.970
22:46245208:A:G	C86R	0.968
22:46245235:A:G	C77R	0.967
22:46245174:A:G	F97S	0.966
22:46245174:A:C	F97C	0.964
22:46245210:A:G	F85S	0.964
22:46245225:A:G	F80S	0.962
22:46245234:C:G	C77S	0.962
22:46245235:A:T	C77S	0.962

dbSNP variants (sampled 300 via entrez): RS1000444257 (22:46245824 C>G,T), RS1000732227 (22:46245595 G>A,C), RS1000757257 (22:46251183 G>A), RS1000889451 (22:46250058 G>T), RS1000941102 (22:46249757 G>A,C,T), RS1001182830 (22:46244584 A>G), RS1001274822 (22:46248654 C>T), RS1002218743 (22:46249143 G>A), RS1002793055 (22:46247178 C>T), RS1002873310 (22:46250882 C>T), RS1002927253 (22:46250738 G>A), RS1003131369 (22:46245913 C>T), RS1003262682 (22:46250001 G>A), RS1003500463 (22:46251064 C>G,T), RS1003855805 (22:46251220 C>T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:109800

GenCC curated gene-disease

Mondo (1): urinary bladder cancer (MONDO:0001187)

Orphanet (1): NON RARE IN EUROPE: Bladder cancer (Orphanet:157980)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

63 associations (top):

Study	Trait	p-value
GCST000561_11	Electrocardiographic traits	3.000000e-10
GCST000872_2	QRS duration	3.000000e-27
GCST001544_1	Colorectal cancer	1.000000e-10
GCST001893_4	Electrocardiographic conduction measures	5.000000e-25
GCST002533_4	QRS duration	4.000000e-07
GCST003598_20	QRS duration	6.000000e-29
GCST003598_47	QRS duration	2.000000e-26
GCST003661_22	Triglycerides	6.000000e-07
GCST003844_45	QRS duration	1.000000e-37
GCST003871_9	QRS complex (Cornell)	1.000000e-09
GCST004645_1	Left ventricular fractional shortening	3.000000e-06
GCST005194_219	Coronary artery disease	1.000000e-06
GCST005195_81	Coronary artery disease	3.000000e-08
GCST006061_4	Atrial fibrillation	8.000000e-11
GCST006061_72	Atrial fibrillation	7.000000e-11
GCST006066_9	Glaucoma (primary open-angle)	4.000000e-09
GCST006414_142	Atrial fibrillation	1.000000e-13
GCST006629_54	Pulse pressure	3.000000e-18
GCST007227_3	QRS duration	4.000000e-25
GCST007269_267	Pulse pressure	4.000000e-16
GCST007552_28	Colorectal cancer	1.000000e-06
GCST007856_89	Colorectal cancer or advanced adenoma	9.000000e-08
GCST008054_14	QRS duration	1.000000e-18
GCST008054_20	QRS duration	5.000000e-20
GCST008422_6	QRS duration	2.000000e-19
GCST009541_4	Heart failure	7.000000e-09
GCST009869_54	Colorectal cancer	2.000000e-06
GCST010173_131	Triglyceride levels	2.000000e-10
GCST010244_99	Triglyceride levels	4.000000e-09
GCST010320_133	PR interval	1.000000e-12

EFO canonical traits (11, from GWAS)

EFO ID	Trait name
EFO:0005054	QRS complex
EFO:0004530	triglyceride measurement
EFO:0007742	QRS amplitude
EFO:0008206	left ventricular systolic function measurement
EFO:0005763	pulse pressure measurement
EFO:0004462	PR interval
EFO:0004327	electrocardiography
EFO:0007885	JT interval
EFO:0010556	Left ventricular mass to end-diastolic volume ratio
EFO:0008205	left ventricular structural measurement
EFO:0004736	aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases methylation	2
bisphenol F	affects cotreatment, increases methylation	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression	1
sodium arsenite	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, decreases expression	1
jinfukang	increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	decreases expression	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	1
Thiram	decreases expression	1
Tretinoin	decreases expression	1
Aflatoxin B1	increases methylation	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	decreases expression	1
Acrylamide	decreases expression	1
Particulate Matter	increases expression	1

Clinical trials (associated diseases)

42 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00384891	PHASE3	TERMINATED	Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
NCT03335059	PHASE3	TERMINATED	Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
NCT04534075	PHASE3	COMPLETED	Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
NCT05822934	PHASE3	ACTIVE_NOT_RECRUITING	Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
NCT00462488	PHASE2	COMPLETED	Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
NCT01374789	PHASE2	TERMINATED	PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer
NCT03529890	PHASE2	UNKNOWN	Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder
NCT04066894	PHASE2	TERMINATED	Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
NCT04861584	PHASE2	RECRUITING	Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
NCT05072600	PHASE2	RECRUITING	Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
NCT05644041	PHASE2	RECRUITING	Intravesical Gem/Doce in Patients With NMIBC
NCT06290687	PHASE2	RECRUITING	Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
NCT06822010	PHASE2	RECRUITING	SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma
NCT07184021	PHASE2	NOT_YET_RECRUITING	Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer
NCT02437539	PHASE1	COMPLETED	Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
NCT02720367	PHASE1	COMPLETED	Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
NCT02722538	PHASE1	COMPLETED	Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
NCT02897765	PHASE1	COMPLETED	A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
NCT03132922	PHASE1	ACTIVE_NOT_RECRUITING	MAGE-A4ᶜ¹º³²T for Multi-Tumor
NCT03636256	PHASE1/PHASE2	COMPLETED	Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NCT03844256	PHASE1/PHASE2	RECRUITING	A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
NCT02139371	EARLY_PHASE1	COMPLETED	Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
NCT00872495	Not specified	RECRUITING	Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
NCT01836978	Not specified	COMPLETED	Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy
NCT02228330	Not specified	UNKNOWN	Prospective Clinical Trial - Obturator Reflex Predictors and Blockage
NCT03433924	Not specified	COMPLETED	An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
NCT03998579	Not specified	COMPLETED	Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer
NCT04525781	Not specified	UNKNOWN	Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
NCT04635566	Not specified	COMPLETED	Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute
NCT04718948	Not specified	UNKNOWN	Multimodal Spectroscopy to Detect Urothelial Cancer in Urine
NCT04812145	Not specified	UNKNOWN	Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma
NCT05335707	Not specified	WITHDRAWN	Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
NCT05621837	Not specified	RECRUITING	Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
NCT05787938	Not specified	UNKNOWN	Role of MRI in Assessment of the Urinary Bladder Wall Post Transurethral Tumor Resection
NCT05946369	Not specified	COMPLETED	Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
NCT06115434	Not specified	UNKNOWN	Comparing Operative, Postoperative and Quality of Life of Patients After Salvage and Radical Cystectomy
NCT06156787	Not specified	COMPLETED	Patterns of Urinary Bladder Cancer in Darfur, Suda
NCT06307704	Not specified	ACTIVE_NOT_RECRUITING	Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients
NCT06582849	Not specified	COMPLETED	Enhanced Assistance During Radiotherapy for Unmet Essential Needs
NCT06675656	Not specified	NOT_YET_RECRUITING	Predictive Role of Microbiome in Patients With Urothelial Carcinoma